STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cancer Prevention Research

• Publication date

  2016-06-07

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1940-6207.CAPR-16-0089PMID 27267892PMCID PMC4970880
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.

  2016cited by this paper
• Chemopreventive Activity of Systemically Administered Curcumin on Oral Cancer in the 4‐Nitroquinoline 1‐Oxide Model

  2015influential reference
• Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer

  2015cited by this paper
• Randomized placebo-controlled trial (RCT) of erlotinib for prevention of oral cancer (EPOC).

  2014cited by this paper
• Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer

  2014influential reference
• Critical analysis of the potential for targeting STAT3 in human malignancy

  2013cited by this paper
• Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer—systematic review and meta‐analysis of trends by time and region

  2013cited by this paper
• Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas.

  2013cited by this paper
• Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer

  2012cited by this paper
• First-inHuman Trial of a STAT 3 Decoy Oligonucleotide in Head and Neck Tumors : Implications for Cancer Therapy

  2012cited by this paper
• First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy.

  2012cited by this paper
• Oral Field Cancerization: An Update

  2012cited by this paper
• The targets of curcumin.

  2011cited by this paper
• Inhibition of EGFR-STAT3 Signaling with Erlotinib Prevents Carcinogenesis in a Chemically-Induced Mouse Model of Oral Squamous Cell Carcinoma

  2010influential reference
• Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T

  2010cited by this paper
• Pilot Randomized Phase II Study of Celecoxib in Oral Premalignant Lesions

  2008cited by this paper
• Stattic: a small-molecule inhibitor of STAT3 activation and dimerization.

  2006cited by this paper
• STAT3 as a therapeutic target in head and neck cancer

  2006cited by this paper
• Chemoprevention of 4-NQO-induced oral carcinogenesis by co-administration of all-trans retinoic acid loaded microspheres and celecoxib.

  2005cited by this paper
• In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy

  2005cited by this paper
• Suppressive effects of a selective cyclooxygenase-2 inhibitor, etodolac, on 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis.

  2004cited by this paper
• Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis.

  2004cited by this paper
• Oral Cavity and Esophageal Carcinogenesis Modeled in Carcinogen-Treated Mice

  2004cited by this paper
• Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide.

  2001cited by this paper
• Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline 1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor,nimesulide

  2001influential reference
• Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo.

  2000cited by this paper
• Body condition scoring: a rapid and accurate method for assessing health status in mice.

  1999cited by this paper
• Second neoplasm in patients with head and neck cancer

  1999cited by this paper
• Comparison of epithelial dysplasia--the 4NQO rat palate model and human oral mucosa.

  1995cited by this paper

• Bergapten exhibits antitumor effects on DMBA-induced oral squamous cell carcinoma via anti-inflammatory and apoptotic activities in hamsters by inhibiting NF-кB and PI3K/Akt/mTOR pathways

  2025cites this paper
• Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker of response to paclitaxel‐plus‐cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

  2024cites this paper
• Effect of docosahexaenoic acid as a chemopreventive agent on experimentally induced hamster buccal pouch carcinogenesis.

  2022cites this paper
• The multifaceted role of STAT3 pathway and its implication as a potential therapeutic target in oral cancer

  2022cites this paper
• The 4-NQO mouse model: An update on a well-established in vivo model of oral carcinogenesis.

  2021cites this paper
• PTPRT Could Be a Treatment Predictive and Prognostic Biomarker for Breast Cancer

  2021cites this paper
• EZH2 Knockout in Oral Cavity Basal Epithelia Causes More Invasive Squamous Cell Carcinomas.

  2021cites this paper
• Luteolin Attenuates Diabetic Nephropathy through Suppressing Inflammatory Response and Oxidative Stress by Inhibiting STAT3 Pathway

  2020cites this paper
• Syringic acid modulates molecular marker–involved cell proliferation, survival, apoptosis, inflammation, and angiogenesis in DMBA‐induced oral squamous cell carcinoma in Syrian hamsters

  2020cites this paper
• Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck

  2017cites this paper
• Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis.

  2017cites this paper
• Bitter Melon Prevents the Development of 4-NQO–Induced Oral Squamous Cell Carcinoma in an Immunocompetent Mouse Model by Modulating Immune Signaling

  2017cites this paper
• Understanding the Multifaceted Role of Human Down Syndrome Kinase DYRK1A.

  2016cites this paper